‘Triple-G’ weight loss drug update: Even on the lowest dose, trial patients lost 12.7% of their weight
01/10/2026-17:18 01/10/2026-17:20 חדשות New York Post דיווח
The drug, the first of its kind to target three metabolic receptors (GLP-1, GIP, and glucagon), is nearing the end of clinical trials and is expected to be submitted to the FDA for approval early next year.
